Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a Nerve-Blocking injection prevent salivary complications after parotid surgery?

NCT ID NCT07812259

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

After surgery to remove a benign parotid tumor, some people develop salivary fistulas or sialoceles, which are collections of saliva that can leak or cause swelling. This pilot study tests whether injecting a long-acting local anesthetic called bupivacaine, combined with a steroid called dexamethasone, directly into the remaining parotid tissue is safe and well tolerated. Ten participants will receive the injection during surgery, and researchers will monitor them for local reactions, nerve problems, allergic responses, and changes in heart rate, blood pressure, and blood sugar. The study also tracks postoperative pain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A long-acting local anesthetic (bupivacaine) mixed with a steroid (dexamethasone), injected into the parotid gland during surgery
What this could lead to
If it proves safe, this injection could become a simple way to reduce salivary complications and pain after parotid surgery.
What could go wrong
This is a very small, early-stage study with only 10 people, so it can only show whether the injection is tolerated, not whether it actually prevents complications. Rare or longer-term side effects may not appear in such a small group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Validated surgical indication for partial parotidectomy for parotid tumor. * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: * The subject is in a period of exclusion determined by a previous study * The patient is under safeguard of justice or state guardianship * History of allergic reaction to amino-amide-type local anesthetics. * Severe neurological history (epilepsy, peripheral neuropathies). * High-risk cardiovascular history (severe hypertension, arrhythmias, complete or incomplete heart block, heart failure, coronary artery disease, treatment with type 2 antiarrhythmic drugs). * Severe liver or kidney disease (severe liver failure or severe kidney failure). * Acidosis, sepsis. * Pregnant or breastfeeding patient. * Patient unable to give informed consent. * Patient for whom it is impossible to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign parotid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier de Nimes

    RECRUITING

    Nîmes, 30000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.